OrsHSA

Phase 2Small molecule

HHealthgen Biotechnology Corp.

OrsHSA is one of 11 small molecule programs targeting Ascites. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AscitesRecruiting

AscitesPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Ascites

#DrugCompanyPhaseTrials

Aldactone

Samsca

1 3

Inderal

WWyeth-Lederle Vaccines

Approved

1 4

Farxiga

AstraZeneca

Phase 2

2 5

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Phase 3

2 6

Proamatine

Takeda

Preclinical

2 7

Keytruda

Merck & Co.

Preclinical

1 8

Opdivo

Bristol-Myers Squibb

Preclinical

1 9

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 10

OrsHSA

HHealthgen Biotechnology Corp.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ascites1 trial

A Phase II Study of OsrHSA in Patients With Decompensated Cirrhotic Ascites

Recruiting·HHealthgen Biotechnology Corp.·Phase 2·NCT04835480·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OrsHSA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OrsHSA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OrsHSA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Healthgen Biotechnology Corp. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHealthgen Biotechnology Corp.

OrsHSA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ascites1 trial

References

Drug Info

Quick Facts

Related News